{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ04937",
      "entity_text" : "terminal complement 9",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ01883",
      "entity_text" : "IgG antibody",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "The elucidation of the pathogenesis from uncontrolled activation of the alternative complement pathway, resulting in formation of the membrane attack complex (MAC) C5b-9 8 has ultimately led to treatment with eculizumab, a monoclonal IgG antibody that binds to C5 and prevents subsequent formation of terminal complement 9.",
  "reading_complete" : "2020-08-03T15:27:10Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-03T15:26:37Z",
  "trigger" : "prevents",
  "evidence" : [ "IgG antibody that binds to C5 and prevents subsequent formation of terminal complement 9" ],
  "pmc_id" : "4974426",
  "score" : 0
}